NEW YORK, Sept. 13, 2017 /PRNewswire/ -- The global cell-based assays market is expected to reach USD 19.92 billion by 2022, at a CAGR of 8.4% from 2017 to 2022. The major factors driving this market are the growing funding and investments in R&D, the increasing prevalence of chronic disorders, rising drug discovery activity, and the advantages of cell-based assays over alternative technologies.On the other hand, the growth of this market is hindered to some extent due to the high cost of instruments and stringent regulatory policies
Read the full report: https://www.reportlinker.com/p05099513
Consumables to register the highest CAGR during the forecast period
The cell-based assays market is classified on the basis of products into consumables, instruments, services and software. The consumables segment is further segmented into reagents, assay kits, microplates, cell lines, probes & labels and other consumables.The consumables segment is expected to grow at the highest rate during the forecast period. This is attributed to the effective and innovative products developed and launched by various players in the market. Such products are encouraging acceptance from consumers.
Pharmaceutical and biotechnology companies to dominate the cell-based assays market during the forecast period
The cell-based assays market is segmented by end users into pharmaceutical and biotechnology companies, academic and government institutions, contract research organizations, and other end users such as hospitals, clinical laboratories, and environmental monitoring laboratories. In 2017, pharmaceutical and biotechnology companies segment is expected to command the largest share and is also estimated to grow at the fastest rate as compared to the other segments. This positive growth can be attributed to the increasing adoption of cell-based assays for drug discovery by these end users, particularly in developed countries across North America and Europe.
APAC is estimated to be the fastest growing regional segment in the global cell-based assays market during the forecast period
Geographically, the cell-based assays market is dominated by North America, followed by Europe. The Asia-Pacific region is estimated to grow at the fastest rate which can be attributed to the increased investments in the healthcare sector, rising expenditure on healthcare along with increased coverage of health insurance, and a rise in disposable incomes especially in countries like China, Japan, and India.
The primary interviews conducted for this report can be categorized as follows:
â€¢ By Company Type - Tier 1 â€" 25 %, Tier 2 â€" 35% and Tier 3 â€" 40%
â€¢ By Designation â€" C level â€" 35%, Director level â€" 25%, Others â€" 40%
â€¢ By Region â€" North America - 43%, Europe â€" 19%, APAC â€" 29%, RoW â€" 9%
The key players in the market are Merck KGaA (Germany), Becton, Dickinson and Company (U.S.), PerkinElmer Inc. (U.S.), Promega Corporation (U.S.), Danaher Corporation (U.S.), GE Healthcare (U.K), Thermo Fisher Scientific Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), BioTek Instruments, Inc. (U.S.), Lonza Group (U.S.), ProQinase GmbH (Germany), Charles River Laboratories, Inc (U.S.), Cisbio Bioassays (France), Miltenyi Biotec (Germany), Cell Biolabs, Inc. (U.S.), DiscoverX Corporation (U.S.), Marin Biologic Laboratories (U.S.), Biospherix, Ltd (U.S.), Essen BioScience Inc. (U.S.), Life Technologies Corporation (U.S.), BioAgilytix Labs. (U.S.), Enzo Life Sciences, Inc. (Switzerland), Aurelia Bioscience Ltd. (U.K. ), Selexis SA (U.S.), and QGel SA (Switzerland).
The report analyses the cell-based assays market by products, applications, end users, and regions. Apart from a comprehensive geographic & product analysis and market sizing, the report also provides the competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise of product portfolios, developments, and strategies adopted by key players to maintain and increase their shares in the market. The market research data, current market size, and forecast of the future trends in the market will help established players as well as new entrants make necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the cell-based assays market.
Key benefits of buying the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned strategies to strengthen their market shares.
The report provides insights on the following pointers:
â€¢ Market Penetration: Comprehensive information on the product portfolios of the top players in the cell-based assays market
â€¢ Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the cell-based assays market
â€¢ Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the cell-based assays market
â€¢ Market Development: Comprehensive information about emerging markets. This report analyzes the market for various cell-based assays across geographies
â€¢ Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell-based assays market
Read the full report: https://www.reportlinker.com/p05099513
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/cell-based-assays-market-by-product-application-end-user-global-forecast-to-2022-300519064.html